Top Health Tech Companies in Boston, MA (574)

Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.

Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.

Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.

Investor Backing & Capital Strength: A majority investment by Nordic Capital and a $125 million financing from Vista Credit Partners are described as fueling accelerated innovation and scale. These developments signal ample capital access to support ongoing expansion.

Product Line Growth: The CareJourney acquisition and subsequent launches of expanded suites (e.g., Ascent, CareJourney, LifeScience) and AI-enabled capabilities broaden the platform’s functionality. These moves indicate a deliberate build-out of offerings across providers, payers, and life sciences.

Market Expansion: New customer business reportedly added more than 2.25 million value-based lives and brought the ecosystem to over 170 million patient records, with the combined portfolio approaching 200 organizations. Active customer and partner engagement at Aggregate 2025 further suggests a deepening commercial footprint.

Resilient & Sustainable Growth: Revenue has risen at a steady mid- to high-single-digit pace—FY2025 grew 8.3% on a normalized basis, with FY2026 Q1 and Q2 up 7.7% and 7.3% respectively, alongside 3.8% active-customer growth. Management also raised its FY2026 net sales outlook, pointing to continued expansion.

Customer Loyalty & Retention: Autoship sales increased 9.3% in Q2 FY2026 to about $2.82 billion and represented 84.6% of total sales, supporting predictable, repeat purchasing. Sales per active customer also edged up to $602, indicating deepening engagement.

Profitability: Adjusted EBITDA climbed 23.7% in Q2 FY2026 to $226.7 million with a 6.8% margin, and net income rose year over year. These gains indicate improving operating earnings alongside growth.

Strong Revenue Growth: Revenue growth is reported at more than 60% year over year in 2024, reinforced by triple‑digit multi‑year growth recognized in Deloitte’s 2025 Technology Fast 500 and 894% three‑year growth in the 2026 Inc. 5000 profile. These indicators collectively point to sustained top‑line momentum across multiple measurement periods.

Market Expansion: The company reports adding five health‑plan clients in 2026 to reach 17 plans and investing in a Hyderabad capability centre. Expansion into additional workflows and new deals in 2025 suggest broader commercial reach and geographic scale.

Investor Backing & Capital Strength: A $90 million Series C in May 2025, bringing total funding to about $200 million, provides resources to extend the platform and AI products. Participation from prominent investors indicates confidence in continued growth and execution capacity.

Strong Revenue Growth: Revenue is growing at double-digit rates, with Q2 2026 up 27% year over year and first-half 2026 up about 25%. Management also raised full-year 2026 guidance to $94–96 million, implying approximately 22–24% growth.

Market Expansion: U.S. activity accelerated, with U.S. analysis volume up 60% year over year in Q2 2026 and major health-system additions. Core genomics customers increased to 542 as of June 30, 2026, from 490 a year earlier.

Customer Loyalty & Retention: Net dollar retention improved to 117% in Q2 2026 (versus 107% a year earlier), indicating greater spending within the installed base. Platform usage also reached a record 115,000 analyses in Q2 2026, up 22% year over year.

Strong Revenue Growth: Revenue is described as rising rapidly, surpassing $750 million in 2025 with 45% year-over-year growth, alongside expanding customer reach. The multi-year trend from roughly $400 million in 2023 to $750 million-plus in 2025 points to sustained expansion across the core business.

Profitability: Profitability is reported for eight consecutive years through 2025, with adjusted EBITDA margin improving by five percentage points in 2025. This indicates expansion has been achieved without relying on sustained operating losses.

Diversified Revenue Streams: Growth extends beyond the registry into healthcare, media, retail, and financial services, with Health up 64% and Media up 35% year over year in 2025. Physical showrooms and fulfillment investments further support multiple avenues for monetization.

Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.

Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.

Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.

Strong Revenue Growth: Feedback suggests revenue expanded rapidly in recent years, highlighted by inclusion in Deloitte’s 2023 Technology Fast 500 and company-reported acceleration around its 2023 financing. Historical performance signals a strong commercial trajectory through the 2019–2022 period.

Market Expansion: Feedback suggests adoption has broadened across major health systems, including a system-wide Northwell rollout and reported reach to more than 15,000 leaders managing over 300,000 staff by 2026. Customer expansions and multi-site deployments indicate a growing footprint across hospitals and ambulatory sites.

Product Line Growth: Feedback suggests continued investment with AI enhancements, a patient-rounding module, and an AI-powered performance insights feature introduced in 2025. Post-acquisition communications in 2026 underscore ongoing product development and innovation recognition.

Strong Revenue Growth: Reported bookings and subscription revenue more than doubled in 2025, indicating accelerating commercial scale. Membership expanded into the millions by mid-2026, reinforcing top-line momentum.

Market Expansion: International membership surged and the company broadened distribution into retail, wholesale, and enterprise channels, extending growth beyond direct-to-consumer. Positioning widened from elite athletes to everyday health, sleep, and longevity use cases.

Investor Backing & Capital Strength: A substantial Series G at a markedly higher valuation brought significant capital from institutional and strategic investors. The raise supported planned headcount expansion and continued product development.

Strong Revenue Growth: Reported three-year revenue growth of 1,061% and placement on the 2026 Inc. 5000 underscore rapid top-line expansion. While absolute revenue is not disclosed, the growth trajectory across 2022–2025 is clearly strong.

Investor Backing & Capital Strength: An $80 million Series C in April 2026, bringing total funding above $160 million and a reported $955 million valuation, signals substantial capital support. Participation from established investors and continued financing provide resources for expansion.

Market Expansion: Customer count reportedly grew from more than 200 in 2024 to over 500 by 2026, including 16 of the top 20 MedTech companies. This indicates broadening adoption across both emerging firms and large enterprises.

Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.

Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.

Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.

Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.

Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.

Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.

Strong Hiring & Retention: Headcount and hiring momentum are evident, with third-party estimates showing growth from roughly the mid‑teens of thousands in 2024 to 20,000+ by 2025–2026 and plans to hire thousands, alongside new capacity such as the Hyderabad operations center. This suggests the company is scaling delivery and talent depth across geographies.

Innovation-Driven Growth: The firm has expanded into AI and digital offerings, including its ZAIDYN platform, acquisitions like Digital Additive and Torrent Consulting, and launches such as Myelo developed with the International Myeloma Foundation. These moves indicate investment beyond traditional consulting into scalable, tech‑enabled services.

Market Expansion: A dedicated mid‑cap pharmaceutical vertical and the opening of an operations center in Hyderabad point to deliberate expansion in target segments and delivery footprint. These steps signal efforts to broaden served markets and strengthen execution capacity.

Strong Revenue Growth: Recurring revenue and contract billings have been rising at low-teen rates since 2022, with expectations for continued double-digit top-line expansion. Reporting also indicates meaningful revenue scale with rapid momentum.

Healthy Cash Flow: Financial analysis points to improving cash generation, with free cash flow expected to increase materially over the near term. This trend signals growing operating efficiency alongside revenue expansion.

Customer Loyalty & Retention: Gross retention remains very high and net revenue retention is described as strong, indicating renewals plus expansion within the existing base. These metrics point to a sticky customer franchise supportive of durable growth.

Strong Revenue Growth: Revenue is described as rising rapidly in recent coverage and company updates, indicating sustained top-line momentum. Independent reporting alongside company milestones points to continued acceleration.

Market Expansion: The company has expanded beyond North America into the UK and Ireland and is gaining traction in segments like higher education, hospitality, and multifamily. Geographic and vertical expansion indicate a broader addressable market and increasing commercial reach.

Product Line Growth: New offerings such as better-for-you sodas, sports and energy drinks, and upgraded dispenser formats signal active portfolio expansion. This broader platform approach is designed to deepen usage across the installed base and attract additional customers.

Strong Revenue Growth: Evidence points to ARR reaching about $210M with continued year-over-year increases, and company statements indicate surpassing $200M in annualized revenue. Feedback suggests upselling and higher average revenue per customer support expansion from existing accounts.

Market Expansion: Adoption reportedly grew from ~410 customers in 2020 to 1,200+ by 2024, with 240 new customers added in 2024 and penetration into top-50 global biopharma firms. Feedback suggests partnerships and geographic breadth bolster reach across biotech and pharma.

Innovation-Driven Growth: Product launches in AI, automation, and broader R&D workflows, plus acquisitions and collaborations (e.g., Lilly TuneLab, NVIDIA) indicate active investment in next-generation capabilities. Feedback suggests these moves expand use cases and deepen platform integration in labs.

Strong Revenue Growth: Recent financial results highlight sustained top-line expansion with rising quarterly revenue and management increasing full‑year guidance, indicating momentum across 2025 and into 2026.

Diversified Revenue Streams: Growth is coming from both diagnostics and data licensing/AI applications, with testing volumes and data contracts expanding rather than reliance on a single line of business.

Customer Loyalty & Retention: Reported net revenue retention above 100% and sizable remaining contract value suggest existing pharmaceutical customers are deepening engagements.

Strong Revenue Growth: Reported ARR surpassed $200 million in June 2026 with five consecutive years of 100% year-over-year growth, indicating rapid scaling. Adoption breadth, including claims of powering one in six U.S. apartments, reinforces the commercial momentum behind that trajectory.

Investor Backing & Capital Strength: A $350 million round in September 2026 at a $4 billion valuation, with major existing investors participating alongside Ontario Teachers’ Pension Plan, underscores substantial access to capital. This financing signals strong confidence to fund continued product development and go-to-market expansion.

Market Expansion: Reach reportedly grew from about one in twelve U.S. apartments in 2024 to one in six in 2026, alongside plans for a second engineering hub in San Francisco. The company is also expanding from leasing into broader property-management workflows and healthcare administration.